Matt Matasar
@drmatasar.bsky.social
Chief of Blood Disorders, Rutgers Cancer Institute. Lymphoma doc, dad of 3, practicing and preaching kindness in both medicine and life.
Disappointed to hear that CARGO’s CD22 #CAR-T results underperformed.
Many other new and promising immunotherapies being developed for aggressive B-cell lymphoma! investors.cargo-tx.com/news-release...
Many other new and promising immunotherapies being developed for aggressive B-cell lymphoma! investors.cargo-tx.com/news-release...
investors.cargo-tx.com
January 30, 2025 at 5:50 PM
Disappointed to hear that CARGO’s CD22 #CAR-T results underperformed.
Many other new and promising immunotherapies being developed for aggressive B-cell lymphoma! investors.cargo-tx.com/news-release...
Many other new and promising immunotherapies being developed for aggressive B-cell lymphoma! investors.cargo-tx.com/news-release...
Happy to be here on BlueSky and off Twitter. Should have left long ago, truthfully. Looking forward to continuing sharing perspectives on lymphoma, academic medicine, etc here with you all :)
January 23, 2025 at 7:56 PM
Happy to be here on BlueSky and off Twitter. Should have left long ago, truthfully. Looking forward to continuing sharing perspectives on lymphoma, academic medicine, etc here with you all :)